OIPE
DEC 1 2 2000
PATENT & TRADEMARK OFFICE
JC59

#130 12/29/00 Tolkey

Patent Docket P1717

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Nicholas Van Bruggen et al. Serial No.: 09/218,481 Filed: December 22, 1998 For: VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTOGONISTS AND USES THEREOF	Group Art Unit: 1642 Examiner: S. Ungar CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on December 5, 2000 Eileen Ly

AMENDMENT UNDER 37 C.F.R. §1.111

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This communication is responsive to the Office Action mailed June 5, 2000. Applicants submit concurrently herewith a Petition for Extension of Time along with the required fee.

Please amend the application as follows and consider the remarks set forth thereafter.

I. AMENDMENTS

In the Specification:

At page 5, line 32, please insert at the end of the paragraph: --1a shows the inhibition effects of different antibodies on the binding of the biotinylated anti-hVEGF antibody A4.6.1 (BIO-A4.6.1); and 1b shows the inhibition effects of different antibodies on the binding of the biotinylated anti-hVEGF antibody A4.6.1 (BIO-A4.6.1).--

C1

At page 6, line 4, please insert at the end of the paragraph: --3a shows the inhibition effects of different anti-hVEGF monoclonal antibodies on the binding of hVEGF to bovine ACE

C2